MEOPA-coupled Hypnosis Versus MEOPA-standard Care in Transesophageal Echocardiography

NCT ID: NCT04398017

Last Updated: 2023-06-05

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-10-14
• Study Completion Date: 2022-08-12

Brief Summary

The primary purpose is to evaluate the impact of hypnosis coupled with MEOPA (Equimolar Mix-ture of Nitrogen Protoxide and Oxygen) on patient comfort when performing transoesophageal echocardiographies.

Further studies on the use of MEOPA alone or the technique of hypnosis alone in the context of an TEE, would not be innovative in any way in view of previous studies or already in progress.

However, service has led to perform TEEs several times by combining MEOPA and hypnosis. Doctors noted a clear reduction in induction time for hypnosis and satisfaction of the patient and operators. This association technique is very often used in pediatrics.

According to one study, it seems that MEOPA increases the threshold of suggestibility and imagination. However suggestion and imagination are two essential notions of the hypnotic technique. To date, doctors have not found any other studies combining MEOPA and hypnosis for adults patients in the context of TEE.

This leads to the following hypothesis: Is there a difference for the patient in terms of for the global management of pain and anxiety between an TEE performed under MEOPA with a standard support and TEE under MEOPA coupled with hypnosis with support standard?

Secondary purposes are:

1. Compare patients' feelings / opinions: patients who have benefited from hypnosis associated with MEOPA versus patients who have been treated with MEOPA alone.

2. Compare patient stress: patients who have benefited from hypnosis associated with MEOPA versus patients who have benefited from MEOPA alone.

3. Compare the operators' feelings / opinions: procedures that have been performed under hypno-analgesia and MEOPA versus standard procedures under MEOPA alone.

4. Failed the TEE procedure

Conditions

Cardiac Diseases

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Standard support

Group Type: ACTIVE_COMPARATOR

Transesophageal echography

Intervention Type: PROCEDURE

Ultrasound examination of the heart using a soft tube. The extremity is inserted through the mouth and positioned in the esophagus behind the heart.

Hypnosis

Group Type: EXPERIMENTAL

Transesophageal echography

Intervention Type: PROCEDURE

Ultrasound examination of the heart using a soft tube. The extremity is inserted through the mouth and positioned in the esophagus behind the heart.

Interventions

Transesophageal echography

Ultrasound examination of the heart using a soft tube. The extremity is inserted through the mouth and positioned in the esophagus behind the heart.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Patient (male or female) of full age without upper age limit
• Patient hospitalized on the site of the Nouvel Hôpital Civil - Strasbourg, with an indication of transesophageal echography with a diagnostic purpose of a cardiac pathology (transesophageal echography scheduled the day after or the very day of selection)
• Patient affiliated to a social security health insurance scheme
• Patient able to understand the objectives and risks related to the research and to give an informed consent dated and signed
• For a woman of childbearing age: negative blood pregnancy test (test performed by the service as part of the care or diagnostic and therapeutic needs related to the patient's hospitalization).

Exclusion Criteria

• Patient with a contraindication to the use of MEOPA
• Patient with little or no understanding of French
• Patient with hearing problems that do not allow hypnosis to occur
• Patient with psychiatric disorders (schizophrenia, psychosis, melancholic depression, hysteria...)
• Disoriented patients
• Patient receiving the following treatments/management:

ophthalmic gas centrally acting drugs: opiates, benzodiazepines and other psychotropic drugs (potentiation of effects).

• Long-term anxiolytics
• Premedications for transesophageal echocardiography by analgesics, Benzodiazepine, hydroxizine, antiemetics and gastric prokinetics or gabapentinoïdes (gabapentin, pregabaline)
• Psychocorporal therapies or complementary therapies during the period of hospitalization (psychotherapy, meditation, acupuncture...)
• Patient in exclusion period (determined by a previous or ongoing study),
• Impossibility of giving the patient informed information (patient in an emergency situation, difficulties in understanding, etc.)
• Pregnancy or breastfeeding reported by the patient
• Patients under curatorship, guardianship, protection of justice
• If the patient has an VAPS >8/10, the transesophageal echocardiography procedure and therefore its inclusion in the research will be postponed.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Strasbourg, France

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

CHU Strasbourg - France

Strasbourg, , France

Countries

France

Other Identifiers

7351

Identifier Type: -

Identifier Source: org_study_id